To search out out more about this drug and its approval, Medscape reached out to Ann S. LaCasce, MD, a lymphoma specialist, partner professor of medication at Harvard Scientific College, and director of the Dana-Farber/Massachusetts Overall Brigham fellowship in hematology/oncology.
Dr Ann S. LaCasce
Medscape: How unusual is relapsed or refractory DLBCL? Like there been any adjustments within the charges of this disease in most modern years?
LaCasce: Roughly 40% of sufferers with DLBCL can hang relapsed or refractory disease. The charges of lymphoma had been rising over the previous a lot of a long time for unclear causes. As right here is a disease predominantly of older adults, rising life expectancy seemingly performs a job. Environmental components also will seemingly be contributing.